Premium
Core needle biopsy for diagnosing lymphoma in cervical lymphadenopathy: Meta‐analysis
Author(s) -
Warshavsky Anton,
Rosen Roni,
Perry Chava,
Muhanidal,
Ungar Omer J.,
CarmelNeiderman Narin Nard,
Fliss Dan M.,
Horowitz Gilad
Publication year - 2020
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.26381
Subject(s) - medicine , lymphoma , cervical lymphadenopathy , radiology , meta analysis , biopsy , confidence interval , retrospective cohort study , disease
Background The diagnostic yield of core needle biopsies (CNB) in cervical lymphadenopathy for lymphoma diagnosis is controversial. The aim of this study was to calculate the accuracy of cervical CNB in diagnosing lymphoma. Methods We conducted a meta‐analysis of all studies on patients presenting with cervical lymphadenopathy and referred to CNB. Patients with a diagnosis other than lymphoma were excluded. All cases diagnosed with lymphoma sufficient to guide treatment based on CNB outcome were considered accurate (actionable) results. A separate meta‐analysis was performed for various lymphoma subtypes. Results Three prospective and 19 retrospective studies, comprising 1120 patients, met the inclusion criteria. The rate of actionable lymphoma diagnoses following CNB ranged from 30% to 96.3%, with a random‐effects model of 82.45% (95% confidence interval [CI] =0.76‐0.88) and a fixed‐effects model of 78.3% (95% CI =0.75‐0.80). Conclusion CNB for cervical lymphadenopathy in lymphoma cases is relatively accurate in guiding treatment.